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Zoonotic  visceral  leishmaniasis,  caused  by  the  intracellular  protozoan  parasite  Leishmania  infantum,  is a
neglected  tropical  disease  that  is  often  fatal  when  untreated.  Dogs  are  considered  the  main  reservoir  of
L.  infantum  in zoonotic  VL  as  the  presence  of  infected  dogs  may  increase  the risk  for human  infection.
Canine  visceral  leishmaniasis  (CVL)  is a major  veterinary  and  public  health  problem  in Southern  Europe,
Middle East  and  South  America.  Control  of  animal  reservoirs  relies  on elimination  of seropositive  dogs  in
endemic  areas.  However,  treatment  of  infected  dogs  is  not  considered  a  favorable  approach  as  this  can
lead to emergence  of  drug  resistance  since  the  same  drugs  are  used  to treat human  infections.  Therefore,
vaccination  against  CVL  remains  the  best  alternative  in  control  of  the  animal  reservoirs.  In  this  study,
we  present  data  on  the  immunogenicity  proﬁle  of  a live  attenuated  parasite  LdCen−/− in a  canine  infec-
tion  model  and  compared  it to that  of Leishmune®, a commercially  available  recombinant  vaccine.  The
immunogenicity  of the  LdCen−/− parasites  was  evaluated  by  antibody  secretion,  production  of  intracyto-
plasmic  and  secreted  cytokines,  activation  and  proliferation  of  T cells.  Vaccination  with  LdCen−/− resulted
in high  immunogenicity  as  revealed  by  the  higher  IgGTotal,  IgG1,  and  IgG2  production  and  higher  lympho-
proliferative  response.  Further,  LdCen−/− vaccinated  dogs  showed  higher  frequencies  of  activated  CD4+
and CD8+  T  cells,  IFN-  production  by CD8+  T  cells,  increased  secretion  of TNF-  and IL-12/IL-23p40  and
decreased  secretion  of  IL-4. These  results  contribute  to the  understanding  of  immunogenicity  elicited  by
live attenuated  L.  donovani  parasites  and, consequently,  to the  development  of  effective  vaccines  against
visceral  leishmaniasis.. Introduction
Visceral leishmaniasis (VL) is a tropical disease with an annual
ncidence of ∼500,000 cases and causes more than 50,000 deaths
ach year [1].  The zoonotic visceral leishmaniasis is caused by the
bligate intracellular protozoan parasite Leishmania infantum (syn.
. chagasi). Dogs are considered the main reservoir of L. infantum in
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zoonotic VL [2] and the presence of infected dogs may increase the
risk for human infection [3]. Canine visceral leishmaniasis (CVL) is
a major veterinary and public health problem not only in endemic
areas but also in Northern Europe, the United States and Canada,
where autochthonous cases or outbreaks of disease are occasionally
reported [4–6].
Control of VL relies on early diagnosis, control of the vector
population and outbreaks in domestic reservoirs and treatment of
infected individuals [7].  These measures can eliminate [8] or dras-
tically reduce the transmission [9] when used over a long period
Open access under the Elsevier OA license.[10]. The availability of new diagnostic kits [1],  efﬁcient vector con-
trol including insecticide spraying and collars impregnated with
deltamethrin for use in animals [11] and new drugs such as milte-
fosine [1] has enabled better control of VL [1,12].  On the other hand,
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considered. For IgG1 and IgG2, sera were added at a 1:100 dilu-
tion. Peroxidase-conjugated Rabbit anti-dog IgGTotal, IgG1 and IgG2786 J.A. Fiuza et al. / Vac
espite the decreased incidence of human and canine VL cases
ollowing elimination of seropositive dogs in endemic areas, this
ontrol strategy provides only a transient effect and is not accepted
idely [13]. Although treatment of dogs usually results in clinical
mprovement, relapses are frequent and in most cases does not
ead to parasitological cure or inhibition of infectivity to the sand
y vector [14]. Further, treatment of infected dogs is not the most
ffective approach as the same drug is used to treat human infec-
ions and possibly hasten the emergence of drug-resistance [7,13].
herefore, vaccination represents the most efﬁcacious method for
he control of zoonotic VL. Widespread application of an effective
accine in dogs would also dramatically decrease transmission of
. infantum to humans [15].
Previous attempts at vaccination based on killed Leishmania
arasites or deﬁned parasite antigens resulted in a limited and
hort-term protection [16]. Live-attenuated vaccines, on the other
and, allow the host immune system to interact with a broad
epertoire of antigens considered to be essential in the develop-
ent of protective immunity and importantly cause no pathology
17–19].  Several methods have been used to attenuate Leish-
ania parasites for vaccination [20]. Speciﬁcally, our labs have
reviously evaluated the protective immunity of an attenuated L.
onovani strain from which centrin has been deleted (LdCen−/−)
n a BALB/C mouse model [18]. Deletion of centrin in L. dono-
ani speciﬁcally affects the cytokinesis and leads to multinucleated
ells and eventual cell death of amastigote forms while the
rowth of promastigote forms is unaffected [21]. Tests to evalu-
te the potential of LdCen−/− parasites as vaccine candidates have
emonstrated the safety, immunogenicity and protection against
nfection with wild type L. donovani in mice and hamster mod-
ls [18]. More importantly, the protection induced by LdCen−/−
arasites was found to be long lasting in these models suggest-
ng that it may  be a leading vaccine candidate for CVL. In the
resent study, we report the immunogenicity proﬁle of LdCen−/−
arasites in dogs, measured by antibody secretion, production
f intracellular and secreted cytokines as well as T cell activa-
ion, proliferation and phenotypic markers. These results were
ompared to those obtained from either placebo (saline) treated
r Leishmune® (a commercially available vaccine) immunized
ogs.
. Material and methods
.1. Parasites and soluble antigen (SLA) preparation
The L. donovani centrin1-deleted (LdCen−/−) parasites were used
21]. The parasite cultures were maintained as previously described
21]. L. infantum promastigote forms (MHOM/BR/1972/BH46] were
rown as described [22]. L. infantum stationary-phase promastig-
tes were harvested, washed three times in PBS and sonicated.
he sonicated material was centrifuged at 18,500 rpm for 90 min  at
◦C. The supernatant was dialyzed against PBS for 24 h and ﬁltered
hrough 0.22 m ﬁlters and stored at −80 ◦C. Protein quantiﬁcation
as performed using Pierce® BCA Protein Assay Kit, as described
y the manufacturer.
.2. Animals and vaccination protocol
This study was approved by the Ethical Committee for the Use
f Experimental Animals of the Federal University of Minas Gerais,
razil (CETEA#122/09] and performed according to the guide-
ines set by the Brazilian Animal Experimental College (COBEA).
ll animals were treated for intestinal parasitic infections, immu-
ized against parvovirus, leptospirosis, distemper, parainﬂuenza
nd hepatitis. Eighteen healthy beagle dogs, 8 months of age were (2013) 1785– 1792
divided into three groups [3 males and 3 females per group).
LdCen−/− group received subcutaneously 1 × 107 LdCen−/− pro-
mastigotes at stationary phase. Leishmune® group received three
subcutaneous doses of vaccine [1 mL  each) with an interval of 21
days between each dose, as recommended by the manufacturer
(Pﬁzer Animal Health, Brazil). Control group received PBS alone. The
immunological parameters ere measured 15 days after the dose of
LdCen−/−.
2.3. Flow cytometric analysis of phenotypic proﬁle and
intracytoplasmic cytokine production
Flow cytometry of the ex vivo and in vitro-stimulated cells
was performed as previously described [23]. For ex vivo analy-
sis, peripheral blood was  collected in Vacutainer tubes containing
EDTA (Becton Dickinson, USA); erythrocytes were lysed using 2 mL
of FACS Lysing Solution (BD Biosciences, USA). The remaining
cells were permeabilized with saponin buffer (Sigma, USA) for
15 min. 2 L of undiluted monoclonal antibodies correspond-
ing to the following cell surface or cytokine markers were
added to the tubes: CD3-FITC (clone CA17.2A12), CD4-FITC or
Alexa Fluor®647 (YKIX302.9), CD8-Alexa Fluor® 647 (YCATE55.9),
CD21-Alexa Fluor®647 (CA2.1D6), CD14-PE (TÜK4), MHC-II-FITC
(YKIX334.2), CD11/18-FITC (YKIX490.6.4), IFN--PE (CC302) and
IL-4-PE (CC303) (AbD Serotec, USA). Cells were incubated in the
dark for 30 min  at RT, washed with PBS twice and ﬁxed in 200 L
of ﬁxative solution (BD Biosciences, USA).
For the analysis of cultures, whole blood was  collected in
heparinized Vacutainer tubes, incubated at a dilution of 1:10
in RPMI-1640 media supplemented with 1.6% l-glutamine, 3%
antibiotic-antimycotic solution (Sigma, USA), 5% of heat inactivated
FBS for 22 h at 37 ◦C and 5% CO2 and pulsed with SLA [10 g/well).
During the last 4 h of culture, Brefeldin A (Sigma, USA) (10 g/mL)
was added [23]. Cells were stained as described above. Acquisitions
were performed in a FACSCan ﬂow cytometer. Data were collected
on 1 × 105 lymphocytes (gated by forward and side scatter) and
analyzed using CellQuest Pro software.
2.4. In vitro proliferative response of lymphocytes
PBMCs were isolated from heparinized blood by density gra-
dient centrifugation as described [24]. Cell culture experiments
were performed in triplicate using 5 × 105 PBMC per well, in a
ﬁnal volume of 1000 L complete RPMI-1640 medium. Cells were
stimulated with 25 g/well of PHA (Sigma, USA) or 10 g/well
of L. infantum SLA. After 72 h incubation, supernatants were
collected for cytokine detection. Cell proliferation analysis was
performed on PBMC labeled with BrdU essentially as described
[25].
2.5. Antibody responses
Antigen-speciﬁc IgGTotal titers and IgG1 and IgG2 levels were
measured by indirect ELISA [26]. Brieﬂy, 96 well micro titer plates
(Nalge Intl., USA) were coated overnight with 5 g/mL of SLA. For
IgGTotal analysis, sera were added at 1:100, 1:200, 1:400, 1:800,
1:1600 and 1:3200 dilutions. The IgG ELISA result is expressed
in titers (dilutions). A positive reaction in a dilution ≥1:200 isantibodies were added at a 1:5000 dilution for 1 h. The substrate,
o-phenylenediamine (Sigma, USA) was  added and absorbance was
measured on SpectraMac-240/PC microplate reader (Molecular
Devices, USA) at 492 nm.
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accinated dogs (Leishmune® and LdCen−/−). The line represents cut-off. a,bSigniﬁca
.6. Cytokines production
The cytokines IL-4, TNF- and IL-12/IL-23p40 were measured
n cell supernatants by a sandwich ELISA (R&D Systems, USA) fol-
owing manufacturer’s instructions. Cytokine concentrations were
alculated from the standard curve using 5-parameter curve ﬁt-
ing software (SOFTmax®Pro-5.3, Molecular Devices, USA). The
ower detection limits were: 31.3 pg/mL for IL-12/IL-23p40 and
L-4; 7.8 pg/mL for TNF-.
.7. Biochemical and hematological analyses
Levels of albumin, AST, ALT, total bilirubin, calcium, total choles-
erol, creatinine, urea, alkaline phosphatase, phosphorus, gamma
T, glucose, total proteins, and whole blood count were evaluated
n the three groups before (day 0) and after (15 days after last dose)
mmunization.
.8. Statistical analysis
Statistical analysis was performed using GraphPad Prism-
5.0 software (GraphPad Software Inc, USA). Non-parametric
ruskal–Wallis test followed by Dunns test was used to com-
are data from three groups (LdCen−/−, Leishmune® and PBS).
ifferences were considered signiﬁcant when a p value ≤0.05 was
btained.
. Results
.1. Vaccination with LdCen−/− induces a strong B cell responseThe B cell responses were assessed to measure the ability
f LdCen−/− and Leishmune® (LM) vaccines to induce antibod-
es. Results showed that all vaccinated animals developed anti-L.
nfantum IgG. Post immunization titers of IgGTotal in LdCen−/− orti-L. infantum IgGtotal titers. Levels of IgG1 (B) and IgG2 (C) of PBS (Control) and
ferences at p < 0.05 compared with Control (PBS) and Leishmune® , respectively.
Leishmune® groups were signiﬁcantly higher (p = 0.02 and
p = 0.0002, respectively) than those observed in the PBS group
(p < 0.0001) (Fig. 1A). Also, increased levels of IgG1 were detected
in Leishmune® and LdCen−/− groups compared to PBS controls
(p = 0.002 and p = 0.02, respectively) (Fig. 1B). Of note, levels of IgG2
were signiﬁcantly higher in LdCen−/− vaccinated dogs compared to
PBS and Leishmune® groups (p = 0.02 and p = 0.0005, respectively)
(Fig. 1C).
3.2. Proliferative response of T cells and B cells
To investigate if LdCen−/− vaccination induces speciﬁc T and
B cell proliferation, we performed cell proliferation assays. The
results were presented as stimulation index. Results showed
that vaccination with LdCen−/− induced an enhanced CD4+ T
cell proliferation in response to SLA compared to Leishmune®
group (p = 0.03) (Fig. 2A). Importantly, immunization with LdCen−/−
induced a much higher proliferation of CD8+ T cells compared to
PBS and Leishmune® groups (p = 0.04 for all) (Fig. 2B). Furthermore,
induction of proliferative response of B cells in LdCen−/− group
was signiﬁcantly higher compared to Leishmune® group (p = 0.03)
(Fig. 2C).
3.3. Immunization with LdCen−/− induces higher activation of
CD8+ T cells
After ascertaining the proliferative responses of the T cells, we
examined the activation proﬁle of the T cells by analyzing surface
expression of MHC-II and CD11/18 markers on CD4+ and CD8+
T cells. Ex vivo analysis of T lymphocyte subsets revealed that
LdCen−/− vaccination induced signiﬁcantly lower MHC-II expres-
sion by CD4+ T cells compared to PBS group (p < 0.03) (Fig. 3A).
In contrast, an elevated MHC-II expression was  observed in CD8+
T cells obtained from LdCen−/− group compared to Leishmune®
and PBS groups (p < 0.0001 and p = 0.01, respectively) (Fig. 3B).
1788 J.A. Fiuza et al. / Vaccine 31 (2013) 1785– 1792
Fig. 2. Speciﬁc cell proliferative response in control (PBS), and vaccinated dogs (Leishmune® and LdCen−/−) groups. Proliferation of CD4+ (A), CD8+ (B) and B cells (C) were
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rssessed  by incorporation of BrdU after stimulation of peripheral blood mononuclea
etween  stimulated cultures and non-stimulated cultures). a,bSigniﬁcant difference
n addition, vaccination with LdCen−/− or Leishmune® induced
ncreased expression of CD11/18 by CD4+ and CD8+ T cell popula-
ions (p < 0.001) compared to non-vaccinated controls (Fig. 3C and
). No major differences were detected in the expression of MHC-II
n CD4+ T cells or CD11/18 in CD4+ and CD8+ populations between
timulated and non-stimulated cells (data not shown).
ig. 3. Ex vivo proﬁle of T cell activation in control (PBS) and vaccinated dogs (Leishmu
MFI)  of MHC  II (A and B) or CD11/18 (C and D) by T CD4+ (A and C) or T CD8+ (B and D) 
espectively. with soluble L. infantum antigen. Results are expressed as stimulation index (Ratio
< 0.05 compared with Control and Leishmune® , respectively.
3.4. LdCen−/− vaccine induces a strong IFN- response in CD8+ T
cellsIntracytoplasmic detection of IFN- and IL-4 within CD4+ and
CD8+ T lymphocytes was  performed immediately after blood col-
lection and in whole blood cultures stimulated with SLA for
ne® and LdCen−/−) groups. Results are expressed as mean ﬂuorescence intensity
cells. a,bSigniﬁcant differences at p < 0.05 compared with Control and Leishmune® ,
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Fig. 4. Ex vivo intracytoplasmic cytokine expression within CD4+ and CD8+ T cells in control (PBS) and vaccinated dogs (Leishmune® and LdCen−/−). Results are expressed
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4 h. This analysis revealed that circulating lymphocytes from
dCen−/− vaccinated group displayed decreased IL-4 levels in CD4+
p = 0.054) and CD8+ (p = 0.891) subpopulations even though this
ifference was  not statistically signiﬁcant (Fig. 4C and D). Impor-
antly, LdCen−/− vaccination induced higher IFN- production in
D8+ T cells (p = 0.0103) (Fig. 4B) and not in CD4+ T cells (Fig. 4A). No
tatistical differences were observed in stimulation index between
ifferent groups analyzed for expression of IL-4 and IFN- within
D4+ and CD8+ T cell subpopulations (data not shown).
.5. LdCen−/− vaccination elicits a pro-inﬂammatory cytokine
roduction
TNF-, IL-12/IL-23p40 and IL-4 were evaluated in SLA stim-
lated PBMC culture supernatants 15 days post immunization.
he results were presented as delta stimulation. LdCen−/− group
howed signiﬁcantly higher levels of TNF- (p < 0.005, Fig. 5A)
nd IL-12p40 (p < 0.0019, Fig. 5B) in PBMCs. Similar enhanced
roduction of TNF-, but not IL-12 was observed in Leishmune®
roup (p < 0.005) (Fig. 5A). The production of IL-4 was  signiﬁcantly
educed in LdCen−/− vaccinated animals compared to PBS and
eishmune® vaccinated dogs (p < 0.05 for all, respectively) (Fig. 5C).
L-10 production was not observed in supernatant from all the
roups (data not shown).
.6. Phenotypic proﬁle of circulating cells (monocytes, B cells and
D4+ and CD8+ T cells) and hematological and biochemical
nalysis
Vaccination with LM or LdCen−/− parasites did not alter the
requencies of CD3+CD4+, CD3+CD8+, CD21+ and CD14+ when
ompared to T0 (before vaccination) (Supplementary Table 1) in the
x vivo analysis. Hematological and biochemical analysis showed
hat vaccination with LM or LdCen−/− parasite did not result in+ (A and C) or T CD8+ (B and D) cells. a,bSigniﬁcant differences at p < 0.05 compared
changes in the entire parameters analyzed Supplementary Table
2).
4. Discussion
Developing vaccines against protozoan parasitic infections
remains a challenge. Major impediments to developing effective
vaccines include discovery of good vaccine candidates, systematic
evaluation of the vaccines in mouse models to establish immune
correlates of protection and importantly, to validate the results
obtained in mouse models in outbred species [27–30].  Genetically
modiﬁed attenuated parasites, which mimic  the wild type infection
but do not cause overt disease confer safety and better protection
over recombinant antigens and thus represent the best approach
[17]. We are reporting on a vaccine formulation against CVL con-
sisting of centrin deleted L. donovani parasite (LdCen−/−) [21]. This
deletion speciﬁcally affects the proliferation of the amastigote
stage that replicates inside macrophages. This attribute contributes
to the safety of LdCen−/− that has been demonstrated in mouse
and hamster models [18]. In the current study, we investigated
the immunogenicity of the LdCen−/− parasites in dogs and com-
pared it with a commercially available canine Leishmania vaccine.
Our results showed that LdCen−/− vaccination is highly immuno-
genic in dogs as evidenced by induction of anti-Leishmania IgGTotal,
IgG1 and IgG2. Antibody responses are commonly found in Leish-
mania vaccines [18,24,31–33] including killed Leishmania [32,34],
recombinant antigens [26,27,31,35,36], and live attenuated para-
sites [18,37]. Remarkably, LdCen−/− showed higher antibodies titers
than Leishmune® in dogs suggesting that live attenuated parasites
allow for the delivery of a broad range of antigens unlike a limited
set of antigens that can be delivered via recombinant vaccines.
However, protection from Leishmania infection is mediated pri-
marily by cytotoxic T cells [38,39].  Previous reports demonstrated
that T cell proliferation in response to Leishmania antigens is an
important biomarker of immunogenicity of a vaccine in mice and
in dogs [24,40]. Consistent with these reports, our results showed
1790 J.A. Fiuza et al. / Vaccine 31 (2013) 1785– 1792
Fig. 5. In vitro cytokine production in control (PBS) and vaccinated dogs (Leishmune® and LdCen−/−). Production of TNF- (A), IL-12p40 (B) and IL-4 (C) was determined after
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eishmune® , respectively.
hat vaccination with LdCen−/− parasites induces a higher T and B
ell proliferation upon stimulation with Leishmania antigen. Such
roliferation was also observed in mice vaccinated with LiSIR2+/−
arasites [19] or Leishmania crude extract with adjuvants in mice
40] or dogs [24,32,34].
To determine the activation status of the T cells subsets, we eval-
ated the expression of MHC-II and CD11/18. Our data showed a
igher expression of MHC-II and CD11/18 in CD8+ lymphocytes in
he LdCen−/− vaccinated dogs suggesting that the vaccine induced
irculating activated T cells. Increased expression of MHC-II repre-
ents an antigenic priming-related immunological event and this
as correlated with protection in asymptomatic dogs [22,32].  Con-
istently, a higher T cell activation was also observed in dogs after
mmunization [35,41].
In order to assess the production of intracytoplasmic cytokines
fter immunization, we analyzed the production of IFN- and IL-
 by CD4+ and CD8+ T cells. Our ex vivo analysis showed that
dCen−/− immunized dogs displayed higher frequencies of CD8+
 cells expressing IFN-, as was observed in immunized mice [18].
D8+ T cells play a critical role in the control of L. donovani infec-
ions [42] by contributing to the formation of granulomas in the
iver of L. donovani infected mice [43]. Further, adoptive transfer
f antigen-speciﬁc CD8+ T cells resulted in 90% reduction in the
plenic parasite burden during chronic VL [44]. Our results showing
he activation of CD8+ T cells and secretion of IFN- in cells isolated
rom LdCen−/− group but not from the Leishmune® group suggest
hat in dogs the protection may  be predominantly associated with
D8+ T cell functions. In contrast, immunization of BALB/C mice
ith LdCen−/− resulted in robust induction of IFN- positive and
NF+ CD4+ as well as CD8+ T cells [18]. Thus the limited induction
f CD4+ T cells and higher frequencies of CD8+ T cells express-
ng IFN- in LdCen−/− immunized dogs observed in the current
tudy might represent a unique attribute of dog immunity further
nderscoring the importance of understanding immune correlates
f protection in different animal models in pre-human vaccinationlts are expressed as stimulation delta (SD), calculated by the difference of cytokine
tandard deviation. a,bSigniﬁcant differences at p < 0.05 compared with Control and
trials. Infection with a wild type L. donovani results in defective
antigen-speciﬁc CD8+ T cell responses [45] due to impaired anti-
gen processing and presentation [42]. Therefore, the activation of
antigen-speciﬁc CD8+ T cells observed in LdCen−/− immunized dogs
might represent a partial restoration of antigen-presentation and
thus CD8+ T cell activation.
In addition, decreased expression of IL-4 by CD4+ and CD8+ T
cells was  demonstrated, suggesting that LdCen−/− altered the Type
1/Type 2 balance towards a protective response, and other vaccine
candidates may  also inﬂuence the Type 1/Type 2 balance [46,47].
However, Leishmune® did not dramatically alter IFN- or IL-4 pro-
duction. LdCen−/− vaccination also induced higher production of
TNF- and IL-12/IL-23p40 in the supernatants of cultures and a
decreased production of IL-4 supporting the concept that this vac-
cine induces a Type 1 response. Similar results were detected in
splenocytes from mice vaccinated with different recombinant anti-
gens [47,48]. It has been shown that resistance to leishmaniasis is
associated with a predominant IFN- and IL-12 production [49,50],
as well as vaccines against leishmaniasis that promote IFN- and
IL-12 are considered to be associated with protective responses
[51,52]. On the other hand, the immune response mediated by Th2
cells is associated with susceptibility, allowing the parasite persis-
tence and progression of the infection [53].
Interestingly, no differences in phenotypic proﬁle of monocytes,
B cells and CD4+ and CD8+ T cells were observed before and after
vaccination. Furthermore, hematological and biochemical analysis
did not show any differences between the groups, which suggests
that the immunization with Leishmune® and LdCen−/− did not
induce any alteration of the number of circulation peripheral blood
cells and also, did not promote alteration in the homeostasis of
hepatic and renal physiological parameters. These results indicate
the safety of such vaccines for use in dogs.
Previous work has shown that LdCen−/− live attenuated vaccine
was immunogenic and protective against VL in mice and ham-
sters [18]. The current work is a step further in demonstrating that
cine 31
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dCen−/− vaccine induces strong antibody production, Type 1 polar-
zation and Type 2 inhibition in dogs, a model more relevant to
he disease because of its important role as a reservoir host. It is
escribed that a vaccine against leishmaniasis required a Type 1
esponse to protect after challenge, as it was demonstrated by other
uthors in dog model [34,54].  Furthermore, it has been shown that
D8+ T cells actively participate in the control of VL and their pres-
nce correlates with protection [42]. This study is a ﬁrst step to
how the potential of genetically modiﬁed live attenuated Leish-
ania donovani vaccine for clinical veterinary use making it highly
ttractive for ﬁeld trials against canine VL. Further studies for evalu-
ting the protection of the LdCen−/− vaccine against visceral canine
eishmaniasis after challenge are in progress.
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